Key Dates

Related Announcements

PAR-21-109 - Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform potential applicants that theNational Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately, in PAR-21-109, Early Stage Investigator Research Using Nonhuman Primate (NHP) Models, (R21 Clinical Trial Not Allowed).

The following text has been added to reflect NIAID's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93. 855

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Interests of Participating Institutes, Centers and Offices

National Institute of Allergy and Infectious Diseases

NIAID will support applications from ESIs using NHP models to conduct basic or translational research within NIAID’s mission to better understand, treat, and prevent infectious and immunologic diseases. Applications should address one or more of the following research areas:

• infectious disease pathogenesis;
• evaluation of therapeutics, including immunologic and pharmacologic interventions to treat and prevent infectious diseases including but not limited to HIV/AIDS;
• evaluation of vaccine candidates, immune correlates of protection and efficacy to prevent infection and/or establishment of infectious diseases, including but not limited to HIV/AIDS;
• transplantation immunology, with the overall goal of establishing or maintaining immunologic tolerance or preventing or treating rejection in recipients of allogeneic solid organ, pancreatic islet, or vascular composite allograft transplants;
• autoimmune disease pathogenesis and mechanisms of action of immune-modulating agents;
• immunologic effects, pathogenesis, biomarkers, and impacts of treatments for radiation-induced injuries; and
• immune system development and function, including across the lifespan and in response to infectious pathogens;

Section VII. Agency Contacts

Scientific/Research Contact(s)

For applications with an HIV/AIDS focus, please direct inquiries to:

Que Dang, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-6181
Email: [email protected]

Please direct all other inquiries to:

Julia Shaw, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3711
Email: [email protected]

Financial/Grants Management Contact(s)

Tamia Powell
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2982
Email: [email protected]

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

For applications with an HIV/AIDS focus, please direct inquiries to:

Que Dang, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-6181
Email: [email protected]

Please direct all other inquiries to:

Julia Shaw, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3711
Email: [email protected]